[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1995

The Evolution of Vitamin D Analogues for the Treatment of Psoriasis

Author Affiliations

The Mount Sinai Medical Center One Gustave L. Levy Place, Box 1048 New York, NY 10029-6574

Arch Dermatol. 1995;131(11):1323-1324. doi:10.1001/archderm.1995.01690230103017
Abstract

OVER THE past decade, vitamin D analogues have been intensively studied for the treatment of a number of dermatologic disorders. They were introduced with tremendous enthusiasm, and for many reasons that enthusiasm has been justified. Here was an entirely new class of medications for dermatologists. In the laboratory, calcipotriene, also called calcipotriol outside the United States, effectively reduced proliferation and induced differentiation of keratinocytes.1,2 These characteristics suggested that this vitamin D3 analogue would be effective in the treatment of psoriasis.

In clinical trials, calcipotriene therapy proved superior to anthralin therapy3 and to an assortment of topical corticosteroids including betamethasone valerate.4 Most recently, it has been shown to be more effective than fluocinonide ointment, a class II corticosteroid that is widely used for the treatment of psoriasis.5

See also page 1305  With this background, calcipotriene therapy was introduced in the United States in 1994. Expectations were high—possibly too high.

First Page Preview View Large
First page PDF preview
First page PDF preview
×